Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CryoCath "encouraged" by cryotherapy trial data:

This article was originally published in Clinica

Executive Summary

Trial data have shown that CryoCath Technologies' catheter cryotherapy system is safe and feasible for treating focal atherosclerosis in peripheral arteries. A 15-patient trial assessed the Quebec, Canada firm's 7 French PermaFrost catheter using a double balloon centering system with a 20mm cooling section between the balloons. It showed that 9 of 11 patients had "symptomatic improvement". All but one of the nine patients had normal pedal artery pulses at follow-up, reported lead researcher Jean-Francois Tanguay, of Canada's Montreal Heart Institute.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT068533

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel